<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/253854-a-unsymmetrically-substituted-phospholane-catalysts-and-a-process-of-preparation-thereof by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 12:19:27 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 253854:A UNSYMMETRICALLY SUBSTITUTED PHOSPHOLANE CATALYSTS AND A PROCESS OF PREPARATION THEREOF</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">A UNSYMMETRICALLY SUBSTITUTED PHOSPHOLANE CATALYSTS AND A PROCESS OF PREPARATION THEREOF</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>A ligand system having the structure of general formula wherein represents stereocenter; R3 and R4 are each independently selected from the group consisting of (C1-C8)-alkyl, (C1-C8)-alkoxy, HO-(C1-C8)-alkyl, (C2-C8)-alkoxyalkyl, (C6-C18)-aryl, (C7-C19)-aralkyl, (C3-C18)-heteroaryl,(C4- C19)-heteroaralkyl,(C1-C8)-alkyl-(C6-C18)-aryl,(C1-C8)-alkyl-(C3-C18)-heteroaryl, (C3-C8)- cycloalkyl, (C1-C8)-alkyl-(C3-C8)-cycloalkyl, and (C3-C8)-cycloalkyl-(C1-C8)-alkyl; R7 an R8 are each independently H, R3 or R3 and R7 and /or R7 and R8 and/or R8 and R4 are joined to one another via a (C3-C5) -alkylene bridge; R1 and R2 are each independently (C1-C8)- alkyl, (C6-C18)-aryl, (C7-C19)-aralkyl, (C3-C18)-heteroaryl, (C4-C19)-heteroaralkyl, (C1-C8)-alkyl- (C6-C18)-aryl, (C1-C8)-alkyl-(C3-C18)-heteroaryl, (C3-C8)-cycloalkyl, (C1-C8)-alkyl-(C3-C8)- cycloalkyl, (C3-C8)-cycloalkyl-(C1-C8)-alkyl, (C1-C8)-alkyl-O, (C6-C18)-aryl-O, (C7-C19)-aralkyl- O, (C3-C8)-cycloalkyl-O, (C1-C8)-alkyl-NH, (C6-C18)-aryl-NH, (C7-C19)-aralkyl-NH, (C3-C8)- cycloalkyl-NH, ((C1-C8)-alkyl)2N, ((C6-C18)-aryl)2N,((C7-C19)-aralkyl)2N, or ((C3-C8)- cycloalkyl)2N; and A is a ring system having the following structure: Wherein Q is O, NH,MH-NH, NR, NOR, NR, S, CH2 or C=C(R)2; R is H, (C1-C8)-alkyl, (C6-C18)-aryl, (C7-C19)-aralkyl, (C1-C8)-alkyl-(C6-C18)-aryl, (C3-C8)- cycloalkyl, (C1-C8)-alkyl-( C3-C8)-cycloalkyl, or (C3-C8)-cycloaalkyl-(C1-C8)-alkyl; R&#x27;is R or R&#x27;&quot;; and R&quot;&#x27; is one or more electron-withdrawing groups selected from the group consisting of flourine, chlorine, CF3 CO, CF3SO2, CF3, and CnF2n+1.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>Unsymmenetrically substituted phospholane catalysts<br>
The present invention is directed to new bisphosphane<br>
ligands and catalysts of the phospholane type. In parti-<br>
cular, the invention relates to ligands of the general<br>
formula (I) .<br><br>
Enantiomerically enriched chiral ligands are used in asym-<br>
metric synthesis and asymmetric catalysis. It is essential<br>
here that the electronic and the stereochemical properties<br>
of the ligands are adjusted optimally to the particular<br>
catalysis problem. An important aspect of the success of<br>
these classes of compounds is attributed to the creation of<br>
a particularly asymmetric environment of the metal centre<br>
by these ligand systems. In order to utilize such an<br>
environment for an effective transfer of chirality, it is<br>
advantageous to control the flexibility of the ligand<br>
system as an inherent limitation of the asymmetric<br>
induction.<br>
Within the substance class of the phosphorus-containing<br>
ligands, cyclic phosphines, especially the phospholanes,<br>
have achieved particular significance. Bidentate, chiral<br>
phospholanes are, for example, the DuPhos and BPE ligands<br>
used in asymmetric catalysis (Cobley, Christopher J.;<br>
Johnson, Nicholas B.; Lennon, Ian C; McCague, Raymond;<br>
Ramsden, James A.; Zanotti-Gerosa, Antonio. The applica-<br>
tion of DuPHOS rhodium(I) catalysts for commercial scale<br><br>
asymmetric hydrogenation. Asymmetric Catalysis on Indus-<br>
trial Scale (2004), 269-282).<br>
In the ideal case, however, a variously modifiable, chiral<br>
ligand basic skeleton is available, which can be varied<br>
within a wide range in relation to its steric and electro-<br>
nic properties.<br>
WO03/084971 presents ligand and catalyst systems with which<br>
extremely positive results can be achieved especially in<br>
hydrogenation. In particular, the catalyst types deriving<br>
from maleic anhydride and the cyclic maleimide apparently<br>
create, in their property as chiral ligands, such a good<br>
environment around the central atom of the complex used<br>
that these complexes are superior to the best hydrogenation<br>
catalysts known to date for some hydrogenations.<br>
Unsymmetrically substituted bisphospholane ligands and<br>
catalysts are presented, for example, by Pringle et al. and<br>
in the European Patent Applications EP1124833, EP1243591,<br>
EP1318155 and EP1318156. These derive substantially from<br>
the known DuPhos ligands (Dalton Transactions 2004, 12,<br>
1901-5) or have flexible -(CH2)- units as a bridge.<br>
However, it is also known that a catalyst is not applicable<br>
equally efficiently to all catalysis problems. Instead, the<br>
situation is such that certain catalysts can be used effi-<br>
ciently for selected catalysis processes and are less suit-<br>
able for other purposes. It is therefore still important to<br>
have a high diversity of catalyst structures ready to be<br>
able to handle a maximum number of catalysis problems<br>
optimally.<br>
It is therefore an object of the present invention to<br>
specify further ligand structures which can be used<br>
successfully in enantioselective catalysis. The ligands<br>
should be preparable in a simple manner from readily<br>
available precursor compounds, be stable in industrial<br><br>
application and, from economical and ecological points of<br>
view, be superior to the known prior art catalysts.<br>
This object is achieved in accordance with the claims.<br>
Claims 1 to 3 relate to the ligand systems. Claims 4 and 5<br>
are directed to inventive complexes. Claim 6 relates to a<br>
preferred embodiment for the preparation of the inventive<br>
ligands and Claims 7 to 15 encompass the use of the<br>
catalysts described in asymmetric synthesis.<br>
By providing ligand systems having the structure of the<br>
general formula (I)<br><br>
in which<br>
* represents a stereocentre,<br>
R3 and R4 are each independently selected from the group<br>
consisting of<br>
(C1-C8)-alkyl, (C1-C8) -alkoxy, HO- (C1-C8) -alkyl,<br>
(C2-C8)-alkoxyalkyl, (C6-C18)-aryl, (C7-C19) -aralkyl,<br>
(C3-C18) -heteroaryl, (C4-C19) -heteroaralkyl,<br>
(C1-C8) -alkyl- (C6-C18)-aryl,<br>
(C1-C8) -alkyl- (C3-C18) -heteroaryl, (C3-C8) -cycloalkyl,<br>
(C1-C8) -alkyl- (C3-C8) -cycloalkyl,<br>
(C3-C8) -cycloalkyl- (C1-C8) -alkyl,<br>
R7 and R8 are each independently H, R3, or<br>
R3 and R7 and/or R7 and R8 and/or R8 and R4 are joined to one<br>
another via a (C3-C5) -alkylene bridge,<br>
R1 and R2 are each independently (C1-C8)-alkyl,<br>
(C6-C18)-aryl, (C7-C19)-aralkyl, (C3-C18)-heteroaryl,<br>
(C4-C19) -heteroaralkyl, (C1-C8) -alkyl- (C6-C18) -aryl,<br><br>
(C1-C8) -alkyl- (C3-C18)-heteroaryl, (C3-C8) -cycloalkyl,<br>
(C1-C8) -alkyl- (C3-C8) -cycloalkyl,<br>
(C3-C8) -cycloalkyl- (C1-C8) -alkyl, (C1-C8) -alkyl-O,<br>
(C6-C18)-aryl-O, (C7-C19)-aralkyl-O, (C3-C8) -cycloalkyl-O,<br>
(C1-C8)-alkyl-NH, (C6-C18)-aryl-NH, (C7-C19) -aralkyl-NH,<br>
(C3-C8) -cycloalkyl-NH, ((C1-C8) -alkyl)2N, ( (C6-C18)-aryl)2N,<br>
((C7-C19)-aralkyl)2N, ((C3-C8) -cycloalkyl)2N,<br>
A is a C2 bridge where both carbon atoms have sp2<br>
hybridization and form part of a 3-, 4-, 5-, 6-, 7- or<br>
8-membered ring system optionally having heteroatoms and<br>
where this ring system is substituted by at least one<br>
electron-withdrawing group selected from the group consist-<br>
ing of fluorine, chlorine, CF3CO, CF3SO2, CF3, CnF2n+1 when A<br>
is a 1,2-bridged phenyl ring, the solution to the stated<br>
object is achieved in an extremely simple but no less<br>
advantageous manner. The ligand systems described can be<br>
used in a simple way in asymmetric synthesis and afford<br>
good to very good results, for example, in the asymmetric<br>
hydrogenation of various organic derivatives, for example<br>
β-acetamidocinnamic esters.<br>
It is advantageous when the part-system A of the inventive<br>
ligand system is substituted on one side by the following<br>
phospholane substructures, where n in this case may assume<br>
a value of 1, 2 or 3 and R may be (C1-C8)-alkyl:<br><br>
For the bridging molecular moiety A, the person skilled in<br>
the art can in principle use any radical useful for the<br><br>
present purpose provided that it has a C2 bridge where both<br>
carbon atoms have sp2 hybridization and where the radical<br>
forms part of a 3-, 4-, 5-, 6-, 7- or 8-membered ring<br>
system. The above-addressed restriction with regard to the<br>
1,2-bridging phenyl rings as the A radical therefore<br>
applies. The above-addressed ring systems may optionally<br>
have one or more heteroatoms. Useful heteroatoms are<br>
especially oxygen, sulphur or nitrogen atoms. Over and<br>
above the above-described sp2 hybridization, they may have<br>
further unsaturation and may be of aromatic nature. They<br>
may be mono- or polysubstituted by further radicals,<br>
especially those selected from the group consisting of<br>
(C1-C8)-alkyl, (C1-C8) -alkoxy, HO-(C1-C8) -alkyl,<br>
(C2-C8)-alkoxyalkyl, (C6-C18)-aryl, (C7-C19) -aralkyl,<br>
(C3-C18) -heteroaryl, (C4-C19) -heteroaralkyl,<br>
(C1-C8) -alkyl- (C6-C18) -aryl,<br>
(C1-C8) -alkyl- (C3-C18) -heteroaryl, (C3-C8) -cycloalkyl,<br>
(C1-C8) -alkyl- (C3-C8) -cycloalkyl,<br>
(C3-C8) -cycloalkyl- (C1-C8) -alkyl.<br>
The ring systems may additionally also have one or more<br>
substituents which exert a negative inductive effect on the<br>
ring system. The negative inductive effect leads to elec-<br>
tron density being withdrawn from the ring system via<br>
σ-bonds and hence also the electron density of the part-<br>
ring system A being reduced. This has a crucial influence<br>
on the basicity of the phosphorus atoms bonded to this<br>
part-system A. Such substituents having a negative induc-<br>
tive effect are in particular formed from atoms or groups<br>
of atoms which, taken alone or together, have a greater<br>
electronegativity than the carbon atom and are thus<br>
electron-withdrawing groups. These are advantageously those<br>
selected from the group consisting of fluorine, chlorine,<br>
CF3CO, CF3SO2, CF3, CnF2n+1.<br><br><br>
in which<br>
Q is O, NH, NH-NH, NR-NR, NOR, NR, S, CH2 or C=C(R)2,<br>
R is H, (C1-C8) -alkyl, (C6-C18) -aryl, (C7-C19)-aralkyl,<br>
(C1-C8) -alkyl- (C6-C18) -aryl, (C3-C8) -cycloalkyl,<br>
(C1-C8) -alkyl- (C3-C8) -cycloalkyl,<br>
(C3-C8) -cycloalkyl- (C1-C8) -alkyl,<br>
R' is R or R"' and<br>
R"' is one or more electron-withdrawing groups selected<br>
from the group consisting of fluorine, chlorine, CF3CO,<br>
CF3SO2, CF3, CnF2n+1, where R' and R"' may each be present<br>
independently in the ring system once or more than once, up<br>
to eight times.<br>
The carbon atoms shown in the general formula (I) and<br>
indicated with an * represent stereogenic centres which<br>
impart chirality to the molecule in question. However, it<br>
is also possible that, over and above the carbon atoms<br>
indicated with an *, further up to all carbon atoms in the<br>
phospholane ring form a stereogenic centre in the ligand<br>
system of the invention. Particularly suitable compounds<br>
are those of the general formula (I) which are present in<br>
maximum enantiomerically enriched form. These are<br>
especially suitable for transferring a chiral induction in<br>
the process underlying the catalysis to the substrate and<br>
are thus capable of generating a high enantiomeric<br>
enrichment in the product too. Particularly advantageous<br><br>
compounds are those of the general formula (I) which have<br>
an enantiomeric enrichment of &gt; 90%, more preferably 91%,<br>
92%, 93%, 94% and most preferably ≥ 95%. Extremely<br>
preferably, the compound of the general formula (I) may<br>
also have an enantiomeric enrichment of &gt; 98%.<br>
The invention also provides complexes which contain the<br>
inventive ligands of the formula (I) and at least one<br>
transition metal.<br>
Suitable complexes, especially of the general formula (V),<br>
contain inventive ligands of the formula (V)<br><br>
where, in the general formula (V), M is a transition metal<br>
centre, L are identical or different coordinating organic<br>
or inorganic ligands and P are inventive bidentate organo-<br>
phosphorus ligands of the formula (I) , S represent coordin-<br>
ating solvent molecules and A represent equivalents of<br>
noncoordinating anions, where x and y are integers greater<br>
than or equal to 1, z, q and r are integers greater than or<br>
equal to 0.<br>
There is an upper limit on the sum of y + z + q by virtue<br>
of the coordination centres available on the metal centres,<br>
but not all coordination sites need be occupied. Preference<br>
is given to complexes with octahedral, pseudooctahedral,<br>
tetrahedral, pseudotetrahedral, square planar coordination<br>
spheres which may also be distorted around the particular<br>
transition metal centre. The sum of y + z + q in such<br>
complexes is less than or equal to 6.<br>
The inventive complexes contain at least one transition<br>
metal atom or ion, in particular of palladium, platinum,<br>
rhodium, ruthenium, osmium, iridium, cobalt, nickel or<br>
copper, in any catalytically relevant oxidation state.<br>
Preference is given to complexes having fewer than four<br>
metal centres, particular preference to those having one or<br><br>
two metal centres. The metal centres may be occupied by<br>
various metal atoms and/or ions.<br>
Preferred ligands L of such complexes are halide, parti-<br>
cularly Cl, Br and I, diene, particularly cyclooctadiene,<br>
norbornadiene, olefin, particularly ethylene and cyclo-<br>
octene, acetato, trifluoroacetato, acetylacetonato, allyl,<br>
methallyl, alkyl, particularly methyl and ethyl, nitrile,<br>
particularly acetonitrile and benzonitrile, and also<br>
carbonyl and hydrido ligands.<br>
Preferred coordinating solvents S are ethers, amines,<br>
particularly triethylamine, alcohols, particularly<br>
methanol, ethanol, i-propanol, and aromatics, particularly<br>
benzene and cumene, DMF or acetone.<br>
Preferred noncoordinating anions A are trifluoroacetate,<br>
trifluoromethanesulphonate, BF4, ClO4, PF6, SbF6 and BAr4,<br>
where Ar may be (C6-C18) -aryl.<br>
The individual complexes may contain different molecules,<br>
atoms or ions of the individual constituents M, P, L, S and<br>
A.<br>
Among the ionic complexes, preference is given to compounds<br>
of the [RhP(diene) ]+A- type where P represents an inventive<br>
ligand of the formula (I) .<br>
The invention also provides a process for preparing the<br>
inventive ligands with differently substituted phosphorus<br>
atoms, in which a compound of the general formula (II) or<br>
(II')<br><br><br><br>
The preparation of the inventive metal-ligand complexes<br>
just shown by way of example can be effected in situ by<br><br>
in which<br>
A may be as defined at the outset,<br>
X is a nucleofugic leaving group and<br>
R1 and R2 may each be as defined above<br>
is reacted with a compound of the general formula (III)<br><br>
in which R3, R4, R7 and R8 may each be as defined above and<br>
M may be a metal from the group consisting of Li, Na, K,<br>
Mg, Ca, or is an organosilyl group, in such a way that an X<br>
group of (II) or (II') is substituted and the absent<br>
phosphine group PR1R2 is subsequently introduced into the<br>
product of the reaction of (III) with (II).<br>
With regard to the preparation of the starting compounds<br>
and conditions in the reactions in question, reference is<br>
made to the following literature (DE10353831; WO03/084971;<br>
EP592552; US5329015).<br>
One possible preparation variant of the ligands and<br>
complexes is detailed in the following scheme:<br><br>
reaction of a metal salt or of a corresponding precomplex<br>
with the ligands of the general formula (I). In addition, a<br>
metal-ligand complex can be obtained by reacting a metal<br>
salt or an appropriate precomplex with the ligands of the<br>
general formula (I) and subsequent isolation.<br>
Examples of such metal salts are metal chlorides, bromides,<br>
iodides, cyanides, nitrates, acetates, acetylacetonates,<br>
hexafluoroacetylacetonates, tetrafluoroborates, perfluoro-<br>
acetates or triflates, especially of palladium, platinum,<br>
rhodium, ruthenium, osmium, iridium, cobalt, nickel or<br>
copper.<br>
Examples of the precomplexes are:<br>
cyclooctadienepalladium chloride, cyclooctadienepalladium<br>
iodide,<br>
1,5-hexadienepalladium chloride, 1,5-hexadienepalladium<br>
iodide, bis(dibenzylideneacetone)palladium, bis(aceto-<br>
nitrile)palladium(II) chloride, bis(acetonitrile)-<br>
palladium(II) bromide, bis(benzonitrile)palladium(II)<br>
chloride, bis(benzonitrile)palladium(II) bromide, bis-<br>
(benzonitrile)palladium(II) iodide, bis(allyl)palladium,<br>
bis(methallyl)palladium, allylpalladium chloride dimer,<br>
methallylpalladium chloride dimer, tetramethylethylene-<br>
diaminepalladium dichloride, tetramethylethylenediamine-<br>
palladium dibromide, tetramethylethylenediaminepalladium<br>
diiodide, tetramethylethylenediaminepalladium dimethyl,<br>
cyclooctadieneplatinum chloride, cyclooctadieneplatinum<br>
iodide, 1,5-hexadieneplatinum chloride,<br>
1,5-hexadieneplatinum iodide, bis(cyclooctadiene)platinum,<br>
potassium ethylenetrichloroplatinate,<br>
cyclooctadienerhodium(I) chloride dimer, norbornadiene-<br>
rhodium(I) chloride dimer,<br><br>
1,5-hexadienerhodium(I) chloride dimer, tris(triphenyl-<br>
phosphine)rhodium(I) chloride,<br>
hydridocarbonyltris(triphenylphosphine)rhodium(I) chloride,<br>
bis(norbornadiene)rhodium(I) perchlorate, bis(norborna-<br>
diene)rhodium(I) tetrafluoroborate, bis(norbornadiene)-<br>
rhodium(I) triflate,<br>
bis(acetonitrilecyclooctadiene)rhodium(I) perchlorate,<br>
bis(acetonitrilecyclooctadiene)rhodium(I) tetrafluoro-<br>
borate, bis (acetonitrilecyclooctadiene)rhodium(I) triflate,<br>
bis(acetonitrilecyclooctadiene)rhodium(I) perchlorate,<br>
bis(acetonitrilecyclooctadiene)rhodium (I) tetrafluoro-<br>
borate, bis(acetonitrilecyclooctadiene)rhodium(I) triflate,<br>
l,5-cyclooctadienerhodium(I) acetoacetonate salts with<br>
halide, triflate, tetrafluoroborate, perchlorate anions,<br>
cyclopentadienerhodium(III) chloride dimer, pentamethyl-<br>
cyclopentadienerhodium(Ill) chloride dimer,<br>
(cyclooctadiene) Ru(η3-allyl)2, ((cyclooctadiene)Ru) 2-<br>
(acetate)4, ((cyclooctadiene) Ru)2 (trif luoroacetate) 4,<br>
RuCl2(arene) dimer, (RuareneI2)2, tris(triphenylphosphine)-<br>
ruthenium(II) chloride, cyclooctadieneruthenium(II)<br>
chloride, OsCl2(arene) dimer, cyclooctadieneiridium(I)<br>
chloride dimer, bis (cyclooctene)iridium(I) chloride dimer,<br>
bis(cyclooctadiene)nickel, (cyclododecatriene)nickel,<br>
tris(norbornene)nickel, nickel tetracarbonyl, nickel(II)<br>
acetylacetonate,<br>
(arene)copper triflate, (arene)copper perchlorate, (arene)-<br>
copper trifluoroacetate, cobalt carbonyl.<br>
The complexes based on one or more metals of the metallic<br>
elements and ligands of the general formula (I), especially<br>
from the group of Ru, Os, Co, Rh, Ir, Ni, Pd, Pt, Cu, may<br>
already be catalysts or be used to prepare inventive<br><br>
catalysts based on one or more metals of the metallic<br>
elements, especially from the group of Ru, Os, Co, Rh, Ir,<br>
Ni, Pd, Pt, Cu.<br>
All inventive complexes are particularly suitable as a<br>
catalyst for asymmetric reactions. Particular preference is<br>
given to their use for asymmetric hydrogenation, hydro-<br>
formylation, rearrangement, allylic alkylation, cyclo-<br>
propanation, hydrosilylation, hydride transfer reactions,<br>
hydroborations, hydrocyanations, hydrocarboxylations, aldol<br>
reactions or Heck reaction.<br>
Very particular preference is given to their use in the<br>
asymmetric hydrogenation of, for example, C=C, C=O or C=N<br>
bonds, in which they have high activities and selectivi-<br>
ties, and hydroformylation. In particular, it is found to<br>
be advantageous here that the ligands of the general<br>
formula (I) can be adjusted very efficiently to the<br>
particular substrate and the catalytic reaction in steric<br>
and electronic terms by virtue of their simple, wide<br>
modifiability.<br>
Particular preference is given to the use of the inventive<br>
complexes or catalysts for hydrogenating E/Z mixtures of<br>
prochiral N-acylated |3-aminoacrylic acids or derivatives<br>
thereof. The N-acyl group used here may preferably be<br>
acetyl, formyl or urethane or carbamoyl protecting groups.<br>
Since both E and Z derivatives of these hydrogenation<br>
substrates can be hydrogenated in similarly good enantio-<br>
meric excesses, it is possible to hydrogenate an E/Z<br>
mixture of prochiral N-acylated β-aminoacrylic acids or<br>
derivatives thereof with excellent enantiomeric enrichments<br>
overall without preceding separation. With regard to the<br>
reaction conditions to be employed, reference is made to<br>
EP1225166. The catalysts mentioned here can be used in an<br>
equivalent manner.<br>
In general, the β-amino acid precursors (acids or esters)<br>
are prepared by literature methods. In the syntheses of the<br><br>
compounds, it is possible to follow the general methods of<br>
Zhang et al. (G. Zhu, Z. Chen, X. Zhang J. Org. Chem. 1999,<br>
64, 6907-6910) and Noyori et al. (W. D. Lubell, M.<br>
Kitamura, R. Noyori Tetrahedron; Asymmetry 1991, 2, 543-<br>
554) and Melillo et al. (D. G. Melillo, R. D. Larsen, D. J.<br>
Mathre, W. F. Shukis, A. W.Wood, J. R. Colleluori J. Org.<br>
Chem. 1987 52, 5143-5150). Starting from the corresponding<br>
3-keto carboxylic esters, reaction with ammonium acetate<br>
and subsequent acylation affords the desired prochiral<br>
enamides.<br>
The hydrogenation products can be converted to the β-amino<br>
acids by measures known to those skilled in the art (analo-<br>
gously to the α-amino acids) .<br>
In principle, the ligands and complexes/catalysts are used<br>
in a manner known to those skilled in the art in the form<br>
of a transfer hydrogenation ("Asymmetric transferhydrogena-<br>
tion of C=O and C=N bonds", M. Wills et al. Tetrahedron:<br>
Asymmetry 1999, 10, 2045; "Asymmetric transferhydrogenation<br>
catalyzed by chiral ruthenium complexes" R. Noyori et al.<br>
Acc. Chem. Res. 1997, 30, 97; "Asymmetric catalysis in<br>
organic synthesis", R. Noyori, John Wiley &amp; Sons, New York,<br>
1994, p.123; "Transition metals for organic Synthesis" Ed.<br>
M. Beller, C. Bolm, Wiley-VCH, Weinheim, 1998, Vol. 2,<br>
p. 97; "Comprehensive Asymmetric Catalysis" Ed.: Jacobsen,<br>
E.N.; Pfaltz, A.; Yamamoto, H., Springer-Verlag, 1999), but<br>
it can also take place in the classical manner with elemen-<br>
tal hydrogen. The process can accordingly work either by<br>
means of hydrogenation with hydrogen gas or by means of<br>
transfer hydrogenation.<br>
In the enantioselective hydrogenation, the procedure is<br>
preferably to dissolve substrates to be hydrogenated and<br>
complex/catalyst in a solvent. As indicated above, the<br>
catalyst is preferably formed from a precatalyst in the<br>
presence of the chiral ligand by reaction or by<br>
prehydrogenation before the substrate is added.<br><br>
Subsequently, hydrogenation is effected at hydrogen<br>
pressure of 0.1 to 100 bar, preferably 0.5 to 10 bar.<br>
The temperature in the hydrogenation should be selected<br>
such that the reaction proceeds sufficiently rapidly at the<br>
desired enantiomeric excesses but side reactions are<br>
prevented as far as possible. Advantageously, operation is<br>
effected at temperatures of -20°C to 100°C, preferably 0°C<br>
to 50°C.<br>
The ratio of substrate to catalyst is determined by econo-<br>
mic considerations. The reaction should proceed suffici-<br>
ently rapidly with minimum complex/catalyst concentration.<br>
However, preference is given to working at a substrate/-<br>
catalyst ratio between 50 000:1 and 10:1, preferably 1000:1<br>
and 50:1. Further substrates hydrogenatable efficiently in<br>
accordance with the invention are α-enamides, itaconates,<br>
unprotected β-enamines.<br>
It is advantageous to use the ligands or complexes which<br>
have been polymer-enlarged in accordance with WO0384971 in<br>
catalytic processes which are carried out in a membrane<br>
reactor. In this case, the continuous mode, which is pos-<br>
sible in this apparatus in addition to the batchwise and<br>
semicontinuous mode, can be carried out as desired in the<br>
crossflow filtration mode (Fig. 2) or as a dead-end<br>
filtration (Fig. 1).<br>
Both process variants have been described in principle in<br>
the prior art (Engineering Processes for Bioseparations,<br>
Ed.: L.R. Weatherley, Heinemann, 1994, 135-165; Wandrey et<br>
al., Tetrahedron Asymmetry 1999, 10, 923-928).<br>
In order that a complex/catalyst appears to be suitable for<br>
use in a membrane reactor, it has to satisfy a wide variety<br>
of criteria. First, it has to be ensured that an appropri-<br>
ately high retention capacity for the polymer-enlarged<br>
complex/catalyst has to be present so that there is satis-<br>
factory activity in the reactor over a desired period<br>
without complex/catalyst having to be replenished continu-<br><br>
(C1-C8)-Alkyl radicals are considered to be methyl, ethyl,<br>
n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,<br>
tert-butyl, pentyl, hexyl, heptyl or octyl including all of<br>
their bonding isomers.<br>
The (C1-C8) -alkoxy radical corresponds to the (C1-C8) -alkyl<br>
radical with the proviso that it is bonded to the molecule<br>
via an oxygen atom.<br>
(C2-C8) -Alkoxyalkyl means radicals in which the alkyl chain<br>
is interrupted by at least one oxygen function, where two<br>
oxygen atoms may not be joined to one another. The number<br>
of carbon atoms specifies the total number of carbon atoms<br>
present in the radical.<br>
A (C3-C5)-alkylene bridge is a carbon chain having three to<br>
five carbon atoms, this chain being bonded to the molecule<br>
in question via two different carbon atoms.<br>
The radicals described in the preceding paragraphs may be<br>
mono- or polysubstituted by halogens and/or nitrogen-,<br>
oxygen-, phosphorus-, sulphur-, silicon-containing<br>
radicals. These are in particular alkyl radicals of the<br>
type mentioned above which have one or more of these<br>
heteroatoms in their chain or which are bonded to the<br>
molecule via one of these heteroatoms.<br>
(C3-C8) -Cycloalkyl is understood to mean cyclopropyl,<br>
cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl radi-<br>
cals, etc. They may be substituted by one or more halogens<br>
and/or nitrogen-, oxygen-, phosphorus-, sulphur-,<br>
silicon-containing radicals and/or have nitrogen, oxygen,<br>
phosphorus, sulphur atoms in the ring, for example 1-, 2-,<br>
3-, 4-piperidyl, 1-, 2-, 3-pyrrolidinyl, 2-,<br>
3-tetrahydrofuryl, 2-, 3-, 4-morpholinyl.<br>
A (C3-C8)-cycloalkyl-(C1-C8)-alkyl radical denotes a cyclo-<br>
alkyl radical as detailed above which is bonded to the<br>
molecule via an alkyl radical as specified above.<br><br>
In the context of the invention, (C1-C8) -acyloxy means an<br>
alkyl radical as defined above which has max. 8 carbon<br>
atoms and is bonded to the molecule via a COO function.<br>
In the context of the invention, (C1-C8) -acyl means an<br>
alkyl radical as defined above which has max. 8 carbon<br>
atoms and is bonded to the molecule via a CO function.<br>
A (C6-C18)-aryl radical is understood to mean an aromatic<br>
radical having 6 to 18 carbon atoms. In particular, this<br>
includes compounds such as phenyl, naphthyl, anthryl,<br>
phenanthryl, biphenyl radicals, or systems of the above-<br>
described type fused to the molecule in question, for<br>
example indenyl systems which may optionally be substituted<br>
by halogen, (C1-C8) -alkyl, (C1-C8) -alkoxy, NH2, NH (C1-C8)-<br>
alkyl, N((C1-C8)-alkyl)2, OH, CF3, NH (C1-C8)-acyl, N((C1-C8)-<br>
acyl)2 , (C1-C8)-acyl, (C1-C8)-acyloxy.<br>
A (C7-C19) -aralkyl radical is a (C6-C18) -aryl radical bonded<br>
to the molecule via a (C1-C8)-alkyl radical.<br>
In the context of the invention, a (C3-C18)-heteroaryl<br>
radical denotes a five-, six- or seven-membered aromatic<br>
ring system composed of 3 to 18 carbon atoms and having<br>
heteroatoms, for example nitrogen, oxygen or sulphur, in<br>
the ring. Such heteroaromatics are considered in particular<br>
to be radicals such as 1-, 2-, 3-furyl, such as 1-, 2-,<br>
3-pyrrolyl, 1-, 2-, 3-thienyl, 2-, 3-, 4-pyridyl, 2-, 3-,<br>
4-, 5-, 6-, 7-indolyl, 3-, 4-, 5-pyrazolyl, 2-, 4-,<br>
5-imidazolyl, acridinyl, quinolinyl, phenanthridinyl, 2-,<br>
4-, 5-, 6-pyrimidinyl. This radical may be substituted with<br>
the same radicals as the abovementioned aryl radical.<br>
A (C4-C19) -heteroaralkyl is understood to mean a hetero-<br>
aromatic system corresponding to the (C7-C19) -aralkyl<br>
radical.<br>
Useful halogens (Hal) include fluorine, chlorine, bromine<br>
and iodine.<br><br>
ally, which is disadvantageous in terms of economic opera-<br>
tion (DE19910691). Moreover, the catalyst used should have<br>
an appropriate TOF (turnover frequency) in order to be able<br>
to convert the substrate to the products within economi-<br>
cally viable periods.<br>
In the context of the invention, polymer-enlarged complex/-<br>
catalyst is understood to mean the fact that one or more<br>
active units (ligands) which cause chiral induction, in a<br>
form suitable for this purpose, are copolymerized with<br>
further monomers, or that these ligands are coupled onto an<br>
already present polymer by methods known to those skilled<br>
in the art. Forms of the units which are suitable for<br>
copolymerization are well known to those skilled in the art<br>
and can be selected freely by them. The procedure is<br>
preferably to derivatize the molecule in question with<br>
groups capable of copolymerization depending on the type of<br>
copolymerization, for example by coupling onto acrylate/-<br>
acrylamide molecules in the case of copolymerization with<br>
(meth)acrylates. In this context, reference is made in<br>
particular to EP 1120160 and the polymer enlargements<br>
detailed there.<br>
At the time of the invention, it was by no means obvious<br>
that the ligand systems presented here permit the develop-<br>
ment of catalyst systems which can be used under substanti-<br>
ally more drastic conditions compared to the known prior<br>
art systems and simultaneously allow the advantageous<br>
properties and capabilities of the prior art systems to be<br>
confirmed. In particular, the unsymmetrically substituted<br>
phospholane-phosphine systems are superior to the symmetri-<br>
cal systems known in the prior art in that they can be<br>
prepared in a less expensive manner since they only require<br>
one molecule of the expensive chiral phospholane unit. In<br>
spite of this, the inventive ligands and catalyst systems<br>
feature high chiral induction in the underlying catalysis.<br><br>
PEG means polyethylene glycol.<br>
N-acyl groups are understood to mean protecting groups<br>
which are generally used customarily in amino acid chemis-<br>
try for the protection of nitrogen atoms. Particular<br>
examples include: formyl, acetyl, Moc, Eoc, phthalyl, Boc,<br>
Alloc, Z, Fmoc, etc.<br>
A nucleofugic leaving group is understood essentially to<br>
mean a halogen atom, especially chlorine or bromine, or so-<br>
called pseudohalides. Further leaving groups may be tosyl,<br>
triflate, nosylate, mesylate.<br>
In the context of the invention, the term enantiomerically<br>
enriched or enantiomeric excess is understood to mean the<br>
proportion of one enantiomer in a mixture with its optical<br>
antipode in a range of &gt; 50% and 
calculated as follows:<br>
([enantiomer1]-[enantiomer2])/([enantiomer1]+[enantiomer2])=ee value<br>
In the context of the invention, the specification of the<br>
inventive complexes and ligands includes all possible<br>
diastereomers, and shall also include the two optical anti-<br>
podes of a particular diastereomer.<br>
The literature references cited in this document are con-<br>
sidered to be included in the disclosure.<br>
In the context of the invention, membrane reactor is under-<br>
stood to mean any reaction vessel in which the molecular<br>
weight-enlarged catalyst is enclosed in a reactor, while<br>
low molecular weight substances are fed to the reactor or<br>
can leave it. The membrane can be integrated directly into<br>
the reaction chamber or be installed outside it in a separ-<br>
ate filtration module in which the reaction solution flows<br>
continuously or intermittently through the filtration<br>
module and the retentate is recycled into the reactor.<br>
Suitable embodiments include those described in W098/22415<br>
and in Wandrey et al. in 1998 yearbook, Verfahrenstechnik<br><br>
Descriptions of the drawings:<br>
Fig. 1 shows a membrane reactor with dead-end filtration.<br>
The substrate I is transferred via a pump 2 into the<br>
reaction chamber 3 which has a membrane 5. In the stirrer-<br>
operated reactor chamber are disposed the catalyst 4, the<br>
product 6 and unconverted substrate 1 as well as the<br>
solvent. Mainly low molecular weight 6 is filtered off<br>
through the membrane 5.<br>
Fig. 2 shows a membrane reactor with crossflow filtration.<br>
Here, the substrate 7 is transferred via the pump 8 into<br>
the stirred reactor chamber in which the solvent, catalyst<br>
9 and product 14 are also disposed. The pump 16 is used to<br>
establish a solvent flow which flows through an optionally<br>
present heat exchanger 12 into the crossflow filtration<br>
cell 15. Here, the low molecular weight product 14 is<br>
removed by means of the membrane 13. High molecular weight<br>
catalyst 9 is subsequently passed back into the reactor 10<br>
with the solvent flow, optionally via the valve 11 and<br>
optionally again through a heat exchanger 12.<br><br><br>
One equivalent (571 mg) of iPr2P-SiMe3 is added slowly at<br>
-78°C to a solution of 666 mg of N-butyldichloromaleimide<br>
in 5 ml. The yellow-orange solution is allowed to warm to<br>
RT and stirred for 1.5 h. Subsequently, another one<br>
equivalent of trimethylsilylphospholane is added under cold<br>
conditions and the mixture is left to stir at RT for a<br>
further 2 hours.<br>
NMR sample:<br>
Compound A: +17.5 ppm and -7.6 ppm (2 x d) in a proportion<br>
of 6% (possibly (THF-d8) monooxide form);<br>
Compound B: -3.4 ppm and -4.1 ppm (2 x s) to an extent of<br>
14% (?)<br>
Compound C: -3.3 ppm and -4.4 ppm (2 x d) to an extent of<br>
74%<br>
The solvent was removed and the residue taken up with 2 ml<br>
of THF and added dropwise at -20°C via cannula to a<br>
solution of one equivalent (1.2 g) of [Rh (cod)2]BF4. After<br>
the precipitation with ether, filtration and washing, the<br>
complex was dried under reduced pressure.<br>
NMR (CDCl3) : Compound A: +73.6 ppm (dd, 15.3 Hz and 147<br>
Hz) and +60.8 ppm (dd, 15.3 Hz and 150 Hz)<br>
to an extent of 11%;<br><br>
Compound B: +71.6 ppm (dd, 16.5 Hz and 150<br>
Hz) and +65.0 ppm (dd, 16.5 Hz and 150 Hz)<br>
to an extent of 79%.<br>
General hydrogenation method<br>
0.005 mmol of precatalyst and 0.5 mmol of prochiral<br>
substrate are initially charged in an appropriate<br>
hydrogenation vessel under an H2 atmosphere and<br>
temperature-controlled at 25°C. After the addition of the<br>
appropriate solvent (7.5 ml of methanol, tetrahydrofuran or<br>
dichloromethane) and pressure equalization (to atmospheric<br>
pressure), the hydrogenation is started by starting the<br>
stirring and commencing with the automatic recording of gas<br>
consumption under isobaric conditions. After the absorption<br>
of gas has ended, the experiment is ended, and conversion<br>
and selectivity of the hydrogenation are determined by<br>
means of gas chromatography.<br>
Hydrogenation at 25°C, 1 bar, 100:1<br><br><br><br>
WE CLAIM;<br>
1. A ligand system having the structure of general formula wherein represents stereocenter; R3<br>
and R4 are each independently selected from the group consisting of (C1-C8)-alkyl, (C1-C8)-<br>
alkoxy, HO-(C1-C8)-alkyl, (C2-C8)-alkoxyalkyl, (C6-C18)-aryl, (C7-C19)-aralkyl, (C3-C18)-<br>
heteroaryl,(C4-C19)-heteroaralkyl,(C1-C8)-alkyl-(C6-C18)-aryl,(C1-C8)-alkyl-(C3-C18)-heteroaryl,<br>
(C3-C8)-cycloalkyl, (C1-C8)-alkyl-(C3-C8)-cycloalkyl, and (C3-C8)-cycloalkyl-(C1-C8)-alkyl;<br>
R7 an R8 are each independently H, R3 or R3 and R7 and /or R7 and R8 and/or R8 and R4 are<br>
joined to one another via a (C3-C5) -alkylene bridge; R1 and R2 are each independently (C1-C8)-<br>
alkyl, (C6-C18)-aryl, (C7-C19)-aralkyl, (C3-C18)-heteroaryl, (C4-C19)-heteroaralkyl, (C1-C8)-alkyl-<br>
(C6-C18)-aryl, (C1-C8)-alkyl-(C3-C18)-heteroaryl, (C3-C8)-cycloalkyl, (C1-C8)-alkyl-(C3-C8)-<br>
cycloalkyl, (C3-C8)-cycloalkyl-(C1-C8)-alkyl, (C1-C8)-alkyl-O, (C6-C18)-aryl-O, (C7-C19)-aralkyl-<br>
O, (C3-C8)-cycloalkyl-O, (C1-C8)-alkyl-NH, (C6-C18)-aryl-NH, (C7-C19)-aralkyl-NH, (C3-C8)-<br>
cycloalkyl-NH, ((C1-C8)-alkyl)2N, ((C6-C18)-aryl)2N,((C7-C19)-aralkyl)2N, or ((C3-C8)-<br>
cycloalkyl)2N; and A is a ring system having the following structure:<br><br>
Wherein<br>
Q is O, NH,MH-NH, NR, NOR, NR, S, CH2 or C=C(R)2;<br>
R is H, (C1-C8)-alkyl, (C6-C18)-aryl, (C7-C19)-aralkyl, (C1-C8)-alkyl-(C6-C18)-aryl, (C3-C8)-<br>
cycloalkyl, (C1-C8)-alkyl-( C3-C8)-cycloalkyl, or (C3-C8)-cycloaalkyl-(C1-C8)-alkyl;<br>
R' is R or R'";and<br><br>
R'" is one or more electron-withdrawing groups selected from the group consisting of flourine,<br>
chlorine, CF3 CO, CF3SO2, CF3, and CnF2n+1.<br>
2.	The ligand system as claimed in claim 1, wherein the formula (I) compound has an<br>
enantiomeric enrichment of &gt;90%.<br>
3.	A complex, comprising: a ligand as claimed in claim 1; and at least one transition metal.<br>
4.	The complex as claimed in claim 3 wherein the at least one transition metal is rhodium or<br>
ruthenium.<br>
5.	A process for preparing the ligand as claimed in claim 1, comprising: reacting a compound of<br>
general formula (II) or (II')<br><br>
With a compound of general formula (III)<br><br>
Thereby forming a P-A bond; and<br><br>
wherein the compound of general formula (II) is reacted, subsequently replacing a remaining -X<br>
with a phosphine group having the structure PR1R2; wherein A is a ring system having the<br>
following structure: <br>
wherein Q is O, NH, NH-NH, NR-NR, NOR, NR,S, CH2 or C=C(R)21;<br>
R is H, (C1-C8)-alkyl, (C6-C18)-aryl, (C7-C19)-aralkyl, (C1-C8)-alkyl-(C6-C18)-aryl, (C3-C8)-<br>
cycloalkyl, (C1-C8)-alkyl-( C3-C8)-cycloalkyl, or (C3-C8)-cycloalkyl-(C1-C8)-alkyl;<br>
R"is R or R'";and<br>
R"' is one or more electron-withdrawing groups selected from the group consisting of fluorine,<br>
chlorine, CF3 CO, CF3SO2, CF3, and CnF2n+1<br>
X is a nucleophilic leaving group; and<br>
R1 and R2 are each independently (C1-C8)-alkyl, (C6-C18)-aryl, (C7-C19)-aralkyl, (C3-C18)-<br>
heteroaryl, (C4-C19)-heteroaralkyl, (C1-C8)-alkyl-(C6-C18)-aryl, (C1-C8)-alkyl-(C3-C18)-<br>
heteroaryl, (C3-C8)-cycloalkyl, (C1-C8)-alkyl-(C3-C8)-cycloalkyl, (C3-C8)-cycloalkyl-(C1-C8)-<br>
alkyl, (C1-C8)-alkyl-O, (C6-C18)-aryl-O, (C7-C19)-aralkyl-O, (C3-C8)-cycloalkyl-O, (C1-C8)-alkyl-<br>
NH, (C6-C18)-aryl-NH, (C7-C19)-aralkyl-NH, (C3-C8)-cycloalkyl-NH, ((C1-C8)-alkyl)2N, ((C6-<br>
C18)-aryl)2N,((C7-C19)-aralkyl)2N,((C3-C8)-cycloalkyl)2N,<br>
R3, R4, R3 and R4 are each independently selected from the group consisting of (C1-C8)-alkyl,<br>
(C1-C8)-alkoxy, HO-(C1-C8)-alkyl, (C2-C8)-alkoxyalkyl, (C6-C18)-aryl, (C7-C19)-aralkyl, (C3-<br>
C18)-heteroaryl, (C4-C19)-heteroaralky, (C1-C8)-alkyl-(C6-C18)-aryl, (C1-C8)-alkyl-(C3-C18)-<br>
heteroaryl, (C3-C8)-cycloalkyl, (C1-C8)-alkyl-(C3-C8)-cycloalkyl, (C3-C8)-cycloalkyl-(C1-C8)-<br><br>
alkyl, R7 and R8 are each independently H, R3, or R3 and R7 and/or R7 and R8 and /or R8 and R4<br>
are joined to one another via a (C3-C5)-alkylene bridge; and<br>
M is a metal selected from the group consisting of Li, Na, K, Mg, and Ca, or is an organosilyl<br>
group.<br>
6.	A process for an asymmetric hydrogenation or hydroformylation of a substrate, comprising:<br>
catalyzing the asymmetric reaction with a catalyst comprising the complex as claimed in<br>
claim 4.<br>
7.	A process for asymmetric hydrogenation or hydroformylation, comprising:<br>
catalyzing the asymmetric reaction with a catalyst comprising the complex as claimed in<br>
claim 4.<br>
8.	The process as claimed in claim 7, wherein an E/Z mixture of prochiral N-acylated β-<br>
aminoacrylic acid or derivatives thereof is hydrogenated.<br>
9.	The process as claimed in claim 6, wherein the asymmetric reaction is a hydrogenation, and<br>
comprises hydrogenation with hydrogen gas or transfer hydrogenation..<br>
10.	The process as claimed in claim 9, wherein the asymmetric reaction comprises hydrogen<br>
gas, and a hydrogen pressure is from 0.1 to 100 bar.<br><br>
11.	The process as claimed in claim 9, wherein a temperature of the asymmetric hydrogenation<br>
is from-20° C. to 100° C.<br>
12.	The process as claimed in claim 6, wherein a substrate/catalyst ratio is from 50 000:1 to<br>
10:1.<br>
13.	The process as claimed in claim 6, wherein the asymmetric reaction catalysis is in a<br>
membrane reactor<br><br><br>
ABSTRACT<br><br>
Title: A UNSYMMETRICALY SUBSTITUTED PHOSPHOLANE CATALYST AND A<br>
PROCESS OF PREPARATION THEREOF<br>
A ligand system having the structure of general formula wherein represents stereocenter; R3 and<br>
R4 are each independently selected from the group consisting of (C1-C8)-alkyl, (C1-C8)-alkoxy,<br>
HO-(C1-C8)-alkyl, (C2-C8)-alkoxyalkyl, (C6-C18)-aryl, (C7-C19)-aralkyl, (C3-C18)-heteroaryl,(C4-<br>
C19)-heteroaralkyl,(C1-C8)-alkyl-(C6-C18)-aryl,(C1-C8)-alkyl-(C3-C18)-heteroaryl,	(C3-C8)-<br>
cycloalkyl, (C1-C8)-alkyl-(C3-C8)-cycloalkyl, and (C3-C8)-cycloalkyl-(C1-C8)-alkyl;<br>
R7 an R8 are each independently H, R3 or R3 and R7 and /or R7 and R8 and/or R8 and R4 are<br>
joined to one another via a (C3-C5) -alkylene bridge; R1 and R2 are each independently (C1-C8)-<br>
alkyl, (C6-C18)-aryl, (C7-C19)-aralkyl, (C3-C18)-heteroaryl, (C4-C19)-heteroaralkyl, (C1-C8)-alkyl-<br>
(C6-C18)-aryl, (C1-C8)-alkyl-(C3-C18)-heteroaryl, (C3-C8)-cycloalkyl, (C1-C8)-alkyl-(C3-C8)-<br>
cycloalkyl, (C3-C8)-cycloalkyl-(C1-C8)-alkyl, (C1-C8)-alkyl-O, (C6-C18)-aryl-O, (C7-C19)-aralkyl-<br>
O, (C3-C8)-cycloalkyl-O, (C1-C8)-alkyl-NH, (C6-C18)-aryl-NH, (C7-C19)-aralkyl-NH, (C3-C8)-<br>
cycloalkyl-NH, ((C1-C8)-alkyl)2N, ((C6-C18)-aryl)2N,((C7-C19)-aralkyl)2N, or ((C3-C8)-<br>
cycloalkyl)2N; and A is a ring system having the following structure:<br><br>
Wherein<br>
Q is O, NH,MH-NH, NR, NOR, NR, S, CH2 or C=C(R)2;<br>
R is H, (C1-C8)-alkyl, (C6-C18)-aryl, (C7-C19)-aralkyl, (C1-C8)-alkyl-(C6-C18)-aryl, (C3-C8)-<br>
cycloalkyl, (C1-C8)-alkyl-( C3-C8)-cycloalkyl, or (C3-C8)-cycloaalkyl-(C1-C8)-alkyl;<br>
R'is R or R'"; and<br>
R"' is one or more electron-withdrawing groups selected from the group consisting of flourine,<br>
chlorine, CF3 CO, CF3SO2, CF3, and CnF2n+1.</td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDM1NDIta29sbnAtMjAwNy1hYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">03542-kolnp-2007-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDM1NDIta29sbnAtMjAwNy1jbGFpbXMucGRm" target="_blank" style="word-wrap:break-word;">03542-kolnp-2007-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDM1NDIta29sbnAtMjAwNy1jb3JyZXNwb25kZW5jZSBvdGhlcnMgMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">03542-kolnp-2007-correspondence others 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDM1NDIta29sbnAtMjAwNy1jb3JyZXNwb25kZW5jZSBvdGhlcnMucGRm" target="_blank" style="word-wrap:break-word;">03542-kolnp-2007-correspondence others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDM1NDIta29sbnAtMjAwNy1kZXNjcmlwdGlvbiBjb21wbGV0ZS5wZGY=" target="_blank" style="word-wrap:break-word;">03542-kolnp-2007-description complete.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDM1NDIta29sbnAtMjAwNy1kcmF3aW5ncy5wZGY=" target="_blank" style="word-wrap:break-word;">03542-kolnp-2007-drawings.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDM1NDIta29sbnAtMjAwNy1mb3JtIDEucGRm" target="_blank" style="word-wrap:break-word;">03542-kolnp-2007-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDM1NDIta29sbnAtMjAwNy1mb3JtIDIucGRm" target="_blank" style="word-wrap:break-word;">03542-kolnp-2007-form 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDM1NDIta29sbnAtMjAwNy1mb3JtIDMucGRm" target="_blank" style="word-wrap:break-word;">03542-kolnp-2007-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDM1NDIta29sbnAtMjAwNy1mb3JtIDUucGRm" target="_blank" style="word-wrap:break-word;">03542-kolnp-2007-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDM1NDIta29sbnAtMjAwNy1ncGEucGRm" target="_blank" style="word-wrap:break-word;">03542-kolnp-2007-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDM1NDIta29sbnAtMjAwNy1pbnRlcm5hdGlvbmFsIHB1YmxpY2F0aW9uLnBkZg==" target="_blank" style="word-wrap:break-word;">03542-kolnp-2007-international publication.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDM1NDIta29sbnAtMjAwNy1pbnRlcm5hdGlvbmFsIHNlYXJjaCByZXBvcnQucGRm" target="_blank" style="word-wrap:break-word;">03542-kolnp-2007-international search report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDM1NDIta29sbnAtMjAwNy1wY3QgcHJpb3JpdHkgZG9jdW1lbnQgbm90aWZpY2F0aW9uLnBkZg==" target="_blank" style="word-wrap:break-word;">03542-kolnp-2007-pct priority document notification.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDM1NDIta29sbnAtMjAwNy1wY3QgcmVxdWVzdCBmb3JtLnBkZg==" target="_blank" style="word-wrap:break-word;">03542-kolnp-2007-pct request form.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDM1NDIta29sbnAtMjAwNy10cmFuc2xhdGVkIGNvcHkgb2YgcHJpb3JpdHkgZG9jdW1lbnQucGRm" target="_blank" style="word-wrap:break-word;">03542-kolnp-2007-translated copy of priority document.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LSgwNy0wMy0yMDEyKS1QRVRJVElPTiBVTkRFUiBSVUxFIDEzNy5wZGY=" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-(07-03-2012)-PETITION UNDER RULE 137.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LSgwNy0wMy0yMDEyKUFCU1RSQUNULnBkZg==" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-(07-03-2012)ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LSgwNy0wMy0yMDEyKUFNQU5ERUQgQ0xBSU1TLnBkZg==" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-(07-03-2012)AMANDED CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LSgwNy0wMy0yMDEyKURFU0NSSVBUSU9OIChDT01QTEVURSkucGRm" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-(07-03-2012)DESCRIPTION (COMPLETE).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LSgwNy0wMy0yMDEyKURSQVdJTkdTLnBkZg==" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-(07-03-2012)DRAWINGS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LSgwNy0wMy0yMDEyKUVYQU1JTkFUSU9OIFJFUE9SVCBSRVBMWSBSRUNFSVZFRC5wZGY=" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-(07-03-2012)EXAMINATION REPORT REPLY RECEIVED.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LSgwNy0wMy0yMDEyKUZPUk0tMS5wZGY=" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-(07-03-2012)FORM-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LSgwNy0wMy0yMDEyKUZPUk0tMi5wZGY=" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-(07-03-2012)FORM-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LSgwNy0wMy0yMDEyKUZPUk0tMy5wZGY=" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-(07-03-2012)FORM-3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LSgwNy0wMy0yMDEyKUZPUk0tNS5wZGY=" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-(07-03-2012)FORM-5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LSgwNy0wMy0yMDEyKU9USEVSUy5wZGY=" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-(07-03-2012)OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LSgwNy0wMy0yMDEyKVBBLUNFUlRJRklFRCBDT1BJRVMucGRm" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-(07-03-2012)PA-CERTIFIED COPIES.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LSgwOC0wOC0yMDEyKS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-(08-08-2012)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LUNPUlJFU1BPTkRFTkNFLnBkZg==" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1rb2xucC0yMDA3LWNvdmVyaW5nIGxldHRlciB0byBmb3JtIDEzLnBkZg==" target="_blank" style="word-wrap:break-word;">3542-kolnp-2007-covering letter to form 13.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LUVYQU1JTkFUSU9OIFJFUE9SVC5wZGY=" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-EXAMINATION REPORT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LUZPUk0gMTMgMS4yLnBkZg==" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-FORM 13 1.2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LUZPUk0gMTMtMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-FORM 13-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LUZPUk0gMTMucGRm" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-FORM 13.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LUZPUk0gMTggMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-FORM 18 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LUZPUk0gMy5wZGY=" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-FORM 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LUZPUk0gNS5wZGY=" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-FORM 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1rb2xucC0yMDA3LWZvcm0tMTgucGRm" target="_blank" style="word-wrap:break-word;">3542-kolnp-2007-form-18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LUdQQS5wZGY=" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-GPA.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LUdSQU5URUQtQUJTVFJBQ1QucGRm" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-GRANTED-ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LUdSQU5URUQtQ0xBSU1TLnBkZg==" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-GRANTED-CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LUdSQU5URUQtREVTQ1JJUFRJT04gKENPTVBMRVRFKS5wZGY=" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-GRANTED-DESCRIPTION (COMPLETE).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LUdSQU5URUQtRFJBV0lOR1MucGRm" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-GRANTED-DRAWINGS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LUdSQU5URUQtRk9STSAxLnBkZg==" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-GRANTED-FORM 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LUdSQU5URUQtRk9STSAyLnBkZg==" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-GRANTED-FORM 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LUdSQU5URUQtU1BFQ0lGSUNBVElPTi5wZGY=" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-GRANTED-SPECIFICATION.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LU9USEVSUy5wZGY=" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LVBBLnBkZg==" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-PA.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LVBFVElUSU9OIFVOREVSIFJVTEUgMTM0LnBkZg==" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-PETITION UNDER RULE 134.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LVJFUExZIFRPIEVYQU1JTkFUSU9OIFJFUE9SVCAxLjEucGRm" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-REPLY TO EXAMINATION REPORT 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LVJFUExZIFRPIEVYQU1JTkFUSU9OIFJFUE9SVC5wZGY=" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-REPLY TO EXAMINATION REPORT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzU0Mi1LT0xOUC0yMDA3LVRSQU5TTEFURUQgQ09QWSBPRiBQUklPUklUWSBET0NVTUVOVC5wZGY=" target="_blank" style="word-wrap:break-word;">3542-KOLNP-2007-TRANSLATED COPY OF PRIORITY DOCUMENT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=YWJzdHJhY3QtMDM1NDIta29sbnAtMjAwNy5qcGc=" target="_blank" style="word-wrap:break-word;">abstract-03542-kolnp-2007.jpg</a></p>
		<br>
		<div class="pull-left">
			<a href="253853-method-and-device-for-winding-a-plurality-of-threads.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="253855-information-management-method-information-management-program-and-information-management-apparatus.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>253854</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>3542/KOLNP/2007</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>35/2012</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>31-Aug-2012</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>29-Aug-2012</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>20-Sep-2007</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>EVONIK DEGUSSA GMBH</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>RELLINGHAUSER STRASSE 1-11, 45128 ESSEN, GERMANY</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>DR. JUAN ALMENA</td>
											<td>SALISWEG 30B 63454 HANAU</td>
										</tr>
										<tr>
											<td>2</td>
											<td>DR. JENS HOLZ</td>
											<td>ALT-ROGGENTINER WEG 14 18196 KESSIN</td>
										</tr>
										<tr>
											<td>3</td>
											<td>DR. ODALYS ESPERANZA ZAYAS VARGAS</td>
											<td>PAULSTRASSE 16 18055 ROSTOCK</td>
										</tr>
										<tr>
											<td>4</td>
											<td>DR. AXEL MONSEES</td>
											<td>FALKSTR. 46 60487 FRANKFURT</td>
										</tr>
										<tr>
											<td>5</td>
											<td>DR. RENAT KADYROV</td>
											<td>WALTER-HESSELBACHSTR. 190 60389 FRANKFURT</td>
										</tr>
										<tr>
											<td>6</td>
											<td>DR. THOMAS RIERMEIER</td>
											<td>SCHULSTRASSE 22A 64372 OBER-RAMSTADT</td>
										</tr>
										<tr>
											<td>7</td>
											<td>PROF. ARMIN BÖRNER</td>
											<td>IM WINKEL 40 18059 ROSTOCK</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>B01J31/24</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/EP2006/060409</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2006-03-02</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>10 2005 014 055.6</td>
									<td>2005-03-23</td>
								    <td>Germany</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/253854-a-unsymmetrically-substituted-phospholane-catalysts-and-a-process-of-preparation-thereof by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 12:19:28 GMT -->
</html>
